Grifols | GRFS - Current Liabilities

Stock Price
7.66
Daily Change
-0.13 -1.67%
Monthly
-10.93%
Yearly
-1.29%
Q2 Forecast
7.46

Grifols reported EUR2.37B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 595K 218K Mar/2026
Arca Biopharma USD 16.63M 1.26M Mar/2026
aTyr Pharma USD 11.7M 101.49M Mar/2026
Bio Path USD 8.68M 819K Sep/2025
Brainstorm Cell Therapeutics USD 11.76M 757K Mar/2026
Capricor Therapeutics USD 33.64M 2.2M Mar/2026
Cara Therapeutics USD 11.04M 2K Dec/2025
Esperion Therapeutics USD 300.36M 451K Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Grifols EUR 2.37B 156.97M Dec/2025
Immunic USD 38.36M 7.74M Mar/2026
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
TherapeuticsMD USD 5.82M 655K Jun/2024